Genotypic and allelic frequencies of SULT1A1 polymorphisms in women receiving adjuvant tamoxifen therapy

J. L. Grabinski, L. S. Smith, G. B. Chisholm, R. Drengler, G. I. Rodriguez, A. S. Lang, S. P. Kalter, A. M. Garner, L. M. Fichtel, J. Hollsten, Bradley H Pollock, J. G. Kuhn

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Human sulfotransferase 1A1 (SULT1A1) is involved in the metabolism of a number of substances including 4-hydroxytamoxifen. It has been shown that patients who are homozygous for the variant SULT1A1 *2/*2 have lower catalytic activity. Previous data has suggested that patients with this particular genotype may be at a greater risk of developing breast cancer or not responding to tamoxifen therapy. To date, there is no data within the Hispanic population on the genotypic and allelic frequencies of the SULT1A1 gene. Two hundred and ninety-six patients were genotyped by either restriction fragment length polymorphism (RFLP) or Pyrosequencing for the SULT1A1 exon 7 polymorphism. The genotypic frequency was 0.47 (*1/*1), 0.40 (*1/*2) and 0.13 (*2/*2) in Caucasians and 0.37 (*1/*1), 0.45 (*1/*2) and 0.18 (*2/*2) in Hispanics. Although Hispanics have a higher genotypic frequency of variant genotypes this difference was not statistically significant (p = 0.26). SULT1A1 genotype did not correlate with any prognostic or predictive markers associated with breast cancer. Future evaluations will assess the functional significance of this polymorphism on survival.

Original languageEnglish (US)
Pages (from-to)13-16
Number of pages4
JournalBreast Cancer Research and Treatment
Volume95
Issue number1
DOIs
StatePublished - Jan 2006
Externally publishedYes

Fingerprint

Sulfotransferases
Tamoxifen
Hispanic Americans
Genotype
Breast Neoplasms
Therapeutics
Restriction Fragment Length Polymorphisms
Exons
Survival
Population
Genes

Keywords

  • Allelic frequency
  • Early stage breast cancer
  • Genotypic frequency
  • Polymorphism
  • SULT1A1

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Grabinski, J. L., Smith, L. S., Chisholm, G. B., Drengler, R., Rodriguez, G. I., Lang, A. S., ... Kuhn, J. G. (2006). Genotypic and allelic frequencies of SULT1A1 polymorphisms in women receiving adjuvant tamoxifen therapy. Breast Cancer Research and Treatment, 95(1), 13-16. https://doi.org/10.1007/s10549-005-9019-5

Genotypic and allelic frequencies of SULT1A1 polymorphisms in women receiving adjuvant tamoxifen therapy. / Grabinski, J. L.; Smith, L. S.; Chisholm, G. B.; Drengler, R.; Rodriguez, G. I.; Lang, A. S.; Kalter, S. P.; Garner, A. M.; Fichtel, L. M.; Hollsten, J.; Pollock, Bradley H; Kuhn, J. G.

In: Breast Cancer Research and Treatment, Vol. 95, No. 1, 01.2006, p. 13-16.

Research output: Contribution to journalArticle

Grabinski, JL, Smith, LS, Chisholm, GB, Drengler, R, Rodriguez, GI, Lang, AS, Kalter, SP, Garner, AM, Fichtel, LM, Hollsten, J, Pollock, BH & Kuhn, JG 2006, 'Genotypic and allelic frequencies of SULT1A1 polymorphisms in women receiving adjuvant tamoxifen therapy', Breast Cancer Research and Treatment, vol. 95, no. 1, pp. 13-16. https://doi.org/10.1007/s10549-005-9019-5
Grabinski, J. L. ; Smith, L. S. ; Chisholm, G. B. ; Drengler, R. ; Rodriguez, G. I. ; Lang, A. S. ; Kalter, S. P. ; Garner, A. M. ; Fichtel, L. M. ; Hollsten, J. ; Pollock, Bradley H ; Kuhn, J. G. / Genotypic and allelic frequencies of SULT1A1 polymorphisms in women receiving adjuvant tamoxifen therapy. In: Breast Cancer Research and Treatment. 2006 ; Vol. 95, No. 1. pp. 13-16.
@article{ab2210b33cd44e5498c84abfcd58a104,
title = "Genotypic and allelic frequencies of SULT1A1 polymorphisms in women receiving adjuvant tamoxifen therapy",
abstract = "Human sulfotransferase 1A1 (SULT1A1) is involved in the metabolism of a number of substances including 4-hydroxytamoxifen. It has been shown that patients who are homozygous for the variant SULT1A1 *2/*2 have lower catalytic activity. Previous data has suggested that patients with this particular genotype may be at a greater risk of developing breast cancer or not responding to tamoxifen therapy. To date, there is no data within the Hispanic population on the genotypic and allelic frequencies of the SULT1A1 gene. Two hundred and ninety-six patients were genotyped by either restriction fragment length polymorphism (RFLP) or Pyrosequencing for the SULT1A1 exon 7 polymorphism. The genotypic frequency was 0.47 (*1/*1), 0.40 (*1/*2) and 0.13 (*2/*2) in Caucasians and 0.37 (*1/*1), 0.45 (*1/*2) and 0.18 (*2/*2) in Hispanics. Although Hispanics have a higher genotypic frequency of variant genotypes this difference was not statistically significant (p = 0.26). SULT1A1 genotype did not correlate with any prognostic or predictive markers associated with breast cancer. Future evaluations will assess the functional significance of this polymorphism on survival.",
keywords = "Allelic frequency, Early stage breast cancer, Genotypic frequency, Polymorphism, SULT1A1",
author = "Grabinski, {J. L.} and Smith, {L. S.} and Chisholm, {G. B.} and R. Drengler and Rodriguez, {G. I.} and Lang, {A. S.} and Kalter, {S. P.} and Garner, {A. M.} and Fichtel, {L. M.} and J. Hollsten and Pollock, {Bradley H} and Kuhn, {J. G.}",
year = "2006",
month = "1",
doi = "10.1007/s10549-005-9019-5",
language = "English (US)",
volume = "95",
pages = "13--16",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - Genotypic and allelic frequencies of SULT1A1 polymorphisms in women receiving adjuvant tamoxifen therapy

AU - Grabinski, J. L.

AU - Smith, L. S.

AU - Chisholm, G. B.

AU - Drengler, R.

AU - Rodriguez, G. I.

AU - Lang, A. S.

AU - Kalter, S. P.

AU - Garner, A. M.

AU - Fichtel, L. M.

AU - Hollsten, J.

AU - Pollock, Bradley H

AU - Kuhn, J. G.

PY - 2006/1

Y1 - 2006/1

N2 - Human sulfotransferase 1A1 (SULT1A1) is involved in the metabolism of a number of substances including 4-hydroxytamoxifen. It has been shown that patients who are homozygous for the variant SULT1A1 *2/*2 have lower catalytic activity. Previous data has suggested that patients with this particular genotype may be at a greater risk of developing breast cancer or not responding to tamoxifen therapy. To date, there is no data within the Hispanic population on the genotypic and allelic frequencies of the SULT1A1 gene. Two hundred and ninety-six patients were genotyped by either restriction fragment length polymorphism (RFLP) or Pyrosequencing for the SULT1A1 exon 7 polymorphism. The genotypic frequency was 0.47 (*1/*1), 0.40 (*1/*2) and 0.13 (*2/*2) in Caucasians and 0.37 (*1/*1), 0.45 (*1/*2) and 0.18 (*2/*2) in Hispanics. Although Hispanics have a higher genotypic frequency of variant genotypes this difference was not statistically significant (p = 0.26). SULT1A1 genotype did not correlate with any prognostic or predictive markers associated with breast cancer. Future evaluations will assess the functional significance of this polymorphism on survival.

AB - Human sulfotransferase 1A1 (SULT1A1) is involved in the metabolism of a number of substances including 4-hydroxytamoxifen. It has been shown that patients who are homozygous for the variant SULT1A1 *2/*2 have lower catalytic activity. Previous data has suggested that patients with this particular genotype may be at a greater risk of developing breast cancer or not responding to tamoxifen therapy. To date, there is no data within the Hispanic population on the genotypic and allelic frequencies of the SULT1A1 gene. Two hundred and ninety-six patients were genotyped by either restriction fragment length polymorphism (RFLP) or Pyrosequencing for the SULT1A1 exon 7 polymorphism. The genotypic frequency was 0.47 (*1/*1), 0.40 (*1/*2) and 0.13 (*2/*2) in Caucasians and 0.37 (*1/*1), 0.45 (*1/*2) and 0.18 (*2/*2) in Hispanics. Although Hispanics have a higher genotypic frequency of variant genotypes this difference was not statistically significant (p = 0.26). SULT1A1 genotype did not correlate with any prognostic or predictive markers associated with breast cancer. Future evaluations will assess the functional significance of this polymorphism on survival.

KW - Allelic frequency

KW - Early stage breast cancer

KW - Genotypic frequency

KW - Polymorphism

KW - SULT1A1

UR - http://www.scopus.com/inward/record.url?scp=32444447357&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=32444447357&partnerID=8YFLogxK

U2 - 10.1007/s10549-005-9019-5

DO - 10.1007/s10549-005-9019-5

M3 - Article

C2 - 16317586

AN - SCOPUS:32444447357

VL - 95

SP - 13

EP - 16

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 1

ER -